The HLA‐IDDM association: Implications for etiology and pathogenesis of IDDM
1987; Wiley; Volume: 3; Issue: 3 Linguagem: Inglês
10.1002/dmr.5610030309
ISSN1099-0895
AutoresJ. Nerup, Thomas Mandrup‐Poulsen, Jens Melvig,
Tópico(s)Diabetes Management and Research
ResumoDiabetes/Metabolism ReviewsVolume 3, Issue 3 p. 779-802 Article The HLA-IDDM association: Implications for etiology and pathogenesis of IDDM Jern Nerup, Jern Nerup Steno Memorial Hospital, Niels Steensensvej 2, DK–2820 Gentofte, DenmarkSearch for more papers by this authorThomas Mandrup-Poulsen, Thomas Mandrup-Poulsen Steno Memorial Hospital, Niels Steensensvej 2, DK–2820 Gentofte, DenmarkSearch for more papers by this authorJens Melvig, Jens Melvig Steno Memorial Hospital, Niels Steensensvej 2, DK–2820 Gentofte, DenmarkSearch for more papers by this author Jern Nerup, Jern Nerup Steno Memorial Hospital, Niels Steensensvej 2, DK–2820 Gentofte, DenmarkSearch for more papers by this authorThomas Mandrup-Poulsen, Thomas Mandrup-Poulsen Steno Memorial Hospital, Niels Steensensvej 2, DK–2820 Gentofte, DenmarkSearch for more papers by this authorJens Melvig, Jens Melvig Steno Memorial Hospital, Niels Steensensvej 2, DK–2820 Gentofte, DenmarkSearch for more papers by this author First published: July 1987 https://doi.org/10.1002/dmr.5610030309Citations: 75AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Singal DP and Blajchman MA: Histocompatibility (HL-A) antigens, lymphocytotoxic antibodies and tissue antibodies in patients with diabetes mellitus. Diabetes 22: 429–432, 1973. 2 Nerup J, Platz P, Andersen OO, Christy M, Lyngsøe J, and Poulsen JE: HLA antigens and diabetes mellitus. Lancet 2: 864–866, 1974. 3 Nerup J: Etiology and pathogenesis of insulin–dependent diabetes mellitus: Present views and future developments, in Etiology and Pathogenesis of Insulin–Dependent Diabetes. JM Martin, RM Ehrlich, and FJ Holland, Eds. Raven Press, New York, 1981, pp 275–288. 4 Svejgaard A, Platz P, and Ryder LP: HLA and disease 1982–a survey. Immunol Rev 70: 193–218, 1983. 5 Bertrams J and Baur MP: Insulin–dependent diabetes mellitus, in Histocompatibility Testing 1984. ED Albert, MP Baur, and WR Mayr, Eds. Springer–Verlag, New York, 1984, pp 348–358. 6 Tiwari JL and Terasaki PI: HLA and Disease Associations. Springer–Verlag, New York, 1985, pp 185–210. 7 Scott J, Nerup J, and Lernmark A: Immunological factors in diabetes mellitus, in Clinical Immunology Update, Reviews for Physicians. WF Rosse, Ed. Elsevier, New York, 1985, pp 53–85. 8 Thomsen M, Platz P, Andersen OO, Christy M, Lyngsøe J, Nerup J, Rasmussen K, Ryder LP, Nielsen LS, and Svejgaard A: MLC typing in juvenile diabetes mellitus and idiopathic Addison's disease. Transplant Rev 22: 125–147, 1975. 9 Platz P, Jakobsen BK, Morling N, Ryder LP, Svejgaard A, Thomsen M, Christy M, Kromann H, Benn J, Green A, and Hauge M: HLA–D and –DR antigens in genetic analysis of insulin dependent diabetes mellitus. Diabetologia 21: 108–115, 1981. 10 Wolf E, Spencer KM, and Cudworth AG: The genetic susceptibility to type 1 (insulin dependent) diabetes: analysis of the HLA–DR association. Diabetologia 24: 224–230, 1983. 11 Svejgaard A, Platz P, and Ryder LP, Insulin–dependent diabetes mellitus: joint results of the 8th workshop study, in Histocompatibility Testing 1980. Terasaki PI, Ed. UCLA Tissue Typing Laboratory, Los Angeles, CA, 1980, pp 638–656. 12 Svejgaard A, Jakobsen BK, Platz P, Ryder LP, Nerup J, Deckert T, Christy M, Borch-Johnsen K, Parving HH, Mølsted–Pedersen L, Kühl C, Buschard C, and Green A: HLA associations in insulin–dependent diabetes: search for heterogeneity in different groups of patients from a homogeneous population. Tissue Antigens, in press. 13 Svejgaard A, Platz P, Ryder LP, Staub–Nielsen L, and Thomsen M: HL–A and disease association: a survey. Transplant Rev 22: 3–43, 1975. 14 Green A: The epidemiological approach to studies of association between HLA and disease. I. The basic measures, concepts and estimation procedures. Tissue Antigens 19: 245–258, 1982. 15 Degnbol B and Green A: Diabetes mellitus among first and second degree relatives of early onset diabetics. Ann Hum Genet 42: 25–47, 1978. 16 Barnett AH, Eff C, Leslie RDG, and Pyke DA: Diabetes in identical twins: a study of 200 pairs. Diabetologia 20: 87–93, 1981. 17 Mustonen A, Ilonen J, Tiilikainen A, Kataja M, and Åkerblom HK: An analysis of epidemiological data in HLA–typed diabetic children. Diabetologia 28: 397–400, 1985. 18 Johnston C, Pyke DA, Cudworth AG, and Wolf E: HLA-DR typing in identical twins with insulin–dependent diabetes: difference between concordant and discordant pairs. Br Med J 286: 253–255, 1983. 19 Nerup J, Christy M, Deckert T, and Egeberg J: Immunological Diseases. M Samter, Ed. Little, Brown and Company, Boston, 1978, pp 1330–1347. 20 Irvine WJ: Classification of idiopathic diabetes. Lancet 1: 638–642, 1977. 21 Rotter JI and Rimoin DL: Heterogeneity in diabetes mellitus–update 1978: evidence for further genetic heterogeneity within juvenile–onset insulin–dependent diabetes mellitus. Diabetes 27: 599–605, 1978. 22 Ludvigsson J, Samuelsson U, Beauforts C, Deschamps I, Drash A, Francois R, Herz G, New M, and Schober E: HLA–DR 3 is associated with a more slowly progressive form of Type 1 (insulin–dependent) diabetes. Diabetologia 29: 207–210, 1986. 23 Ebberhardts MS, Wagener DK, Orchard TJ, LaPorte RE, Cavender DE, Rabin BS, Atchinson RW, Kuller LH, Drash AL, and Becker DJ: HLA heterogeneity of insulin-dependent diabetes mellitus at diagnosis: The Pittsburgh IDDM study. Diabetes 34: 1247–1252, 1985. 24 Knip M, Ilonen J, Mustonen A, and Åkerblom HK: Evidence of an accelerated B cell destruction in HLA Dw3/Dw4 heterozygous children with Type 1 (insulin-dependent) diabetes. Diabetologia 29: 347–351, 1986. 25 Nerup J, Platz P, Andersen OO, Christy M, Egeberg J, Lyngsøe J, Poulsen JE, Ryder LP, Thomsen M, and Svejgaard A: HLA, autoimmunity and insulin–dependent diabetes mellitus, in The Genetics of Diabetes Mellitus. W Creutzfeldt and JV Neel, Eds. Springer–Verlag, New York, 1976, pp 106–115. 26 Rotter JI, Anderson CE, Rubin R, Congleton JE, Terasaki PI, and Rimoin DL: HLA genotypic study of insulin–dependent diabetes: the excess of DR3/DR4 heterozygotes allows rejection of the recessive hypothesis. Diabetes 32: 169–174, 1983. 27 Svejgaard A and Ryder LP: HLA genotype and genetic models of insulin–dependent diabetes mellitus. Ann Hum Genet 45: 293–298, 1981. 28 Dausset J and Hors J: Immunogenetics of insuli–dependent diabetes. Diabetes Res 1: 115–123, 1984. 29 Bodmer WF: The HLA system 1984, in Histocompatibility Testing 1984. ED Albert, MP Baur, and WR Mayr, Eds. Springer–Verlag, New York, 1984, pp 11–22. 30 Hansen GS, Svejgaard A, and Claesson MH: T cell clones restricted to "hybrid" HLA-D antigens? J Immunol 128: 2497–2499, 1982. 31 Charron DJ, Lotteau V, and Turmel P: Hybrid HLA–DC antigens provide molecular evidence for gene trnas–complementation. Nature 312: 157–159, 1984. 32 Mølvig J, McDevitt GS, Thomsen AC, Thomsen M, and Nerup J: Studies of restriction by HLA class II molecules of the proliferative response of antigen specific T cell clones generated in diabetics. XVII Annual Meeting of the Scandinavian Society for Immunology, June 3–8, 1986. 33 Sheehy MJ, Rowe JR, and MacDonald: A particular subset of HLA–DR4 accounts for all or most of the DR4 association in type 1 diabetes. Diabetes 34: 942–944, 1985. 34 Green A, Svejgaard A, Platz P, Ryder LP, Jakobsen BK, Morton NE, and MacLean CJ: The genetic susceptibility to insulin–dependent diabetes mellitus (IDDM): combined segregation and linkage analysis. Genet Epidemiol 2: 1–15, 1985. 35 Sheehy MJ, Rowe JR, Fuller TC, Yunis EJ, and Gabbay KH: A minor subset of HLA-DR3 haplotypes is preferentially increased in Type 1 (insulin–dependent) diabetes. Diabetologia 28: 891–894, 1985. 36 Bach FH, Rich SS, Barbosa J, and Segall M: Insulin–dependent diabetes–associated HLA–D region encoded determinants. Hum Immunol 12: 59–64, 1985. 37 Suciu–Foca N, Rubinstein P, Nicholson J, Susinno E, Weiner J, Godfrey M, Hardy M, Rayfield E, and Reemstsma K: Juvenile diabetes mellitus and the HLA system. Transplant Proc 11: 1309–1313, 1979. 38 Mustonen A, Ilonen J, Surcel HM, and Åkerblom HK: A "new" DR4 associated D specificity "Ja" in Type 1 (insulin–dependent) diabetes: A9, Bw16, DJA, Dr4 haplotype. Diabetologia 27: 126–128, 1984. 39 Christau B, Åkerblom HK, Joner G, Dahlquist G, Ludvigsson J, and Nerup J: Incidence of childhood insulin–dependent diabetes mellitus in Denmark, England, Norway and Sweden. Acta Endocrinol 245 (Suppl 1): 68–80, 1981. 40 Owerbach D, Lernmark Å, Platz P, Ryder LP, Rask L, Peterson PA, and Ludvigsson J: HLA–D region beta–chain DNA endonuclease fragments differ between HLA–DR identical healthy and insulin-dependent diabetic patients. Nature 303: 815–817, 1983. 41 Cohen–Hagenauer O, Robbins E, Massart C, Busson M, Deschamps I, Hors J, La–louel JM, Dausset J, and Cohen D: A systematic study of HLA class II-beta DNA restriction fragments in insulin–dependent diabetes mellitus. Proc Natl Acad Sci USA 82: 3335–3339, 1985. 42 Stetler D, Grumet FC, and Ehrlich HA: Polymorphic restriction endonuclease sites linked to the HLA-DR alpha gene: localization and use as genetic markers of insulin–dependent diabetes. Proc Natl Acad Sci USA 82: 8100–8104, 1985. 43 Fesenstein H, Awad J, Hitman GA, Cubush SW, Groves AV, Cassell P, Ollier W, and Sachs JA: New HLA DNA polymorphisms associated with autoimmune diseases. Nature 322: 64–67, 1986. 44 Owerbach D, Hägglöff B, Lernmark A, and Holmgren G: Susceptibility to insulin–dependent diabetes defined by restriction enzyme polymorphism of HLA–D region genomic DNA. Diabetes 323: 958–965, 1984. 45 Dausset J and Cohen D: HLA at the gene level, in Histocompatibility Testing 1984. ED Albert, MP Baur, and WR Mayr, Eds. Springer–Verlag, New York, 1984, pp 22–27. 46 Morris PJ, Irvine WJ, Gray RS, Duncan LJP, Vaughan H, McCallum FJ, Campbell CJ, and Farquhar JW: HLA and pancreatic islet cell antibodies in diabetes. Lancet 2: 652–653, 1976. 47 Christy M, Nerup J, Bottazzo GF, Doniach D, Platz P, Svejgaard A, Ryder LP, and Thomsen M: Association between HLA–B8 and autoimmunity in juvenile diabetes mellitus. Lancet 2: 142, 1976. 48 Richens ER, Quilley J, and Hartog M: Immunological features of juvenile onset diabetic patients correlated to HLA type. Clin Exp Immunol 36: 198–204, 1979. 49 Lendrum R, Walker G, Cudworth AG, Woodrow JC, and Gamble DR: HLA– linked genes and islet–cell antibodies in diabetes mellitus. Br Med J 1: 1565–1567, 1976. 50 Batchelor JR and Morris PJ: Juvenile onset diabetes: joint report, in Histocompatibility Testing 1977. Bodmer W, Ed. Munksgaard, Copenhagen, 1978, pp 211–213. 51 Mustonen A, Ilonen J, Åkerblow HK, and Tiilikainen A: An islet cell antibody negative form of insulin–dependent diabetes mellitus (IDD) associated with HLA antigens A9 and Bw16. Clin Exp Immunol 48: 213–217, 1982. 52 Ginsberg–Fellner F, Dobersen MJ, Witt ME, Rayfield EJ, Rubinstein P, and Notkins AL: HLA antigens, cytoplasmic islet cell antibodies, and carbohydrate tolerance in families of children with insulin–dependent diabetes mellitus. Diabetes 31: 292–298, 1982. 53 Eisenbarth GS, Srikanta S, Fleischnick E, Ganda OP, Jackson RA, Brink SJ, Soeldner JS, Edmond JY, and Alper C: Progressive autoimmune beta cell insufficiency: occurrence in the absence of high-risk HLA alleles DR3, DR4. Diabetes Care 8: 477–480, 1985. 54 Bruserud Ø and Thorsby E: T lymphocyte responses to Coxsackie B4 and mumps virus. I. Influence of HLA–DR restriction elements. Tissue Antigens 26: 41–50, 1985. 55 Bruserud Ø, Jerwell J, and Thorsby E: HLA–DR3 and –DR4 control T–lymphocyte responses to mumps and Coxsackie B4 virus: studies on patients with Type 1 (insulin–dependent) diabetes and healthy subjects. Diabetologia 28: 420–426, 1985. 56 Gepts W and LeCompte P: The pancreatic islets in diabetes. Am J Med 70: 105–115, 1981. 57 Nerup J: The clinical and immunological association of diabetes mellitus and. Addison's disease, in Immunity and Autoimmunity in Diabetes Mellitus. PA Bastenie and W Gepts, Eds. Excerpta Medica, Amsterdam, 1974, pp 149–152. 58 Nerup J, Andersen OO, Bendixen G, Egeberg J, Gunnarson R, Kromann H, and Poulsen JE: Cell mediated immunity in diabetes mellitus. Proc R Soc Med 67: 506–513, 1974. 59 Bottazzo GF, Florin–Christensen A, and Doniach D: Islet cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279–1283, 1974. 60 Lernmark A, Freedman ZR, Hofmann C, Rubinstein AH, Steiner DF, Jackson RL, Winter RJ, and Traisman HS: Islet cell surface antibodies in juvenile diabetes mellitus. N Engl J Med 299: 375–380, 1978. 61 Palmer JP, Asplin CM, Clemens P, Lyen K, Tatpati O, Ragliu P, and Paquette TL: Insulin antibodies in insulin dependent diabetes mellitus before insulin treatment. Science 222: 1337–1339, 1983. 62 Srikanta S, Ganda OP, Eisenbarth GS, and Soeldner JS: Islet cell antibodies and beta cell function in monozygotic triplets and twins initially discordant for type 1 diabetes mellitus. N Engl J Med 308: 322–325, 1983. 63 Borch–Johnsen K, Joner G, Mandrup–Poulsen T, Christy M, Zachau–Christensen B, Kastrup K, and Nerup J: Relation between breast–feeding and incidence rates of insulin–dependent diabetes mellitus: a hypothesis. Lancet 2: 1083–1086, 1984. 64 Boitard C, Debray–Sachs M, Pouplard A, Assan R, and Hamburger J: Lymphocytes from diabetics suppress insulin–release in vitro. Diabetologia 21: 41–46, 1981. 65 Kanatsuna T, Lernmark Å, Rubinstein AH, and Steiner DF: Block in insulin release from column–perfused pancreatic beta cells induced by islet cell surface antibodies and complement. Diabetes 30: 231–234, 1981. 66 Mandrup–Poulsen T, Nerup J, Stiller CR, Marner B, Bille G, Heinrichs D, Martell R, Dupre J, Keown PA, Jenner MR, Rodger NW, Wolfe B, Graffenried Bv, and Binder C: Disappearance and reappearance of islet cell cytoplasmic antibodies in cyclos–porin–treated insulin–dependent diabetics. Lancet 1: 599–602, 1985. 67 Sibley RK, Sutherland DER, Goetz FC, and Michael AF: Recurrent diabetes mellitus in the pancreatic iso– and allograft period: a light and electronmicroscopic and immunohistochemical analysis of four cases. Lab Invest 53: 132–144, 1985. 68 Prowse SJ, Simeonovic CJ, Lafferty KJ, Bond BC, Magi CE, and Mackie D: Allogeneic islet transplantation without recipient immunosuppression, in Methods in Diabetes Research, Vol 1. Laboratory Methods Part B. J Larner and SL Pohl, Eds. John Wiley & Sons, New York, 1984, pp 253–257. 69 Weringer EG and Like AA: Immune attack on pancreatic islet transplants in the spontaneously diabetic biobreeding/Worcester (BB/W) rat is not MHC restricted. J Immunol 134: 2383–2386, 1985. 70 Prowse SJ, Bellgrau D, and Lafferty KJ: Islet allografts are destroyed by disease occurrence in the spontaneously diabetic BB–rat. Diabetes 35: 110–114. 71 Bottazzo GF, Pujol–Borrell R, Hanafusa T, and Feldman M: Hypothesis: role of aberrant HLA-DR expression and antigen presentation in the induction of endocrine autoimmunity. Lancet 2: 1115–1119, 1983. 72 Baekkeskov S, Kanatsuna T, Klareskog L, Nielsen DA, Peterson PA, Rubinstein AH, Steiner DF, and Lernmark A: Expression of major histocompatibility antigens on pancreatic islet cells. Proc Natl Acad Sci USA 78: 6456–6460, 1981. 73 Bottazzo GF, Dean BM, McNally JM, MacKay EH, Swift PGF, and Gamble R: In situ characterization of autoimmune phenomena and expression of HLA–molecules in the pancreas in diabetic insulitis. N Engl J Med 313: 353–360, 1985. 74 Foulis AK, Liddle CN, Farquharson MA, Richmond JA, and Weir RS: The histopa–thology of the pancreas in type I (insulin-dependent) diabetes mellitus: a 25–year review of diabetes in patients under 20 years of age in the United Kingdom. Diabeto–logia 29: 267–274, 1986. 75 Bottazzo GF, 21st Annual Meeting, Scandinavian Society for the Study of Diabetes, May 22–24, 1986. 76 Dean BM, Walker R, Bone AJ, Baird JD, and Cooke A: Pre-diabetes in the spontaneously diabetic BB/E rat: lymphocyte subpopulations in the pancreatic infiltrate and expression of rat MHC class II molecules in endocrine cells. Diabetologia 28: 464–466, 1985. 77 Weringer EJ and Like AA: T cell subsets and class II antigens in islets transplanted into BioBreeding/Worcester (BB/W) rats. Diabetes 35 (Suppl 1): 69A, 1986. 78 Iwatani Y, Iitaka M, Rastogi B, Row VV, and Volpé R: Thyrocyte HLA–DR expression is a secondary phenomenon. Endocrinology (Suppl) 118: 238A, 1986. 79 Paschke R, Teuber J, Schwedes U, and Usadel KH: Significance of antiidiotypic antibody and DR–AG expression for the pathophysiology of Graves disease. Endocrinology (Suppl) 118: 236A, 1986. 80 McDevitt HO: The role of H-2 I region genes in regulation of the immune response. J Immunogenet 8: 287–295, 1981. 81 Dausset J and Contu L: The MHC and immune response in man, in Immunology 80. Progress in Immunology IV. M Fougerau and J Dausset, Eds. Academic Press, London, 1980, pp 513–529. 82 Werdelin O: Immune response genes. Allergy 37: 451–461, 1982. 83 Rocklin R, Bendtzen K, and Greineder D: Mediators of immunity: lymphokines and monokines. Adv Immunol 29: 55–136, 1980. 84 Palacios R: Monoclonal antibodies against human la antigens stimulate monocytes to secrete interleukin 1. Proc Natl Acad Sci USA 82: 6652–6656, 1985. 85 MacSween JM, Eastwood SL, Cohen AD, Rajaraman K, and Fox RA: Lymphokine responses to concanavalin A stimulation: association with HLA–Dr antigens. Clin Immunol Immunopathol 32: 368–377, 1984. 86 Caruso C and Bellina L: B8, DR3 antigens and production of human leucocyte migration inhibitory factor (LIF) by mononuclear cells stimulated with concanavalin A (Con A). Tissue Antigens 22: 167–169, 1983. 87 Mandrup–Poulsen T, Bendtzen K, Nielsen JH, Bendixen G, and Nerup J: Cytokines cause functional and structural damage to isolated islets of Langerhans. Allergy 40: 424–429, 1985. 88 Mandrup–Poulsen T, Bendtzen K, Nerup J, Egeberg J, and Nielsen JH: Mechanisms of pancreatic islet cell destruction: dose–dependent cytotoxic effect of soluble blood mononuclear cell mediators on isolated islets of Langerhans. Allergy 41: 250–259, 1986. 89 Mandrup–Poulsen T, Bendtzen K, Nerup J, Dinarello CA, Svenson M, and Nielsen JH: Affinity purified human interleukin–1 is cytotoxic to isolated islets of Langerhans. Diabetologia 29: 63–67, 1986. 90 Bendtzen K, Mandrup–Poulsen T, Nerup J, Nielsen JH, Dinarello CA, and Svenson M: Cytotoxicity of human pI 7 interleukin–1 for pancreatic islets of Langerhans. Science 232: 1545–1547, 1986. 91 Auron PE, Webb AC, Rosenwasser LJ, Mucci SF, Rich A, Wolff SM, and Dinarello CA: Nucleotide sequence of human monocyte interleukin–1 precursor cDNA. Proc Natl Acad Sci USA 81: 7907–7911, 1984. 92 Oppenheim JJ, Kovacs EJ, Matsushima K, and Durum SK: There is more than one interleukin-1. Immunol Today 7: 45–56, 1986. 93 Bendtzen K, Barington T, Mandrup-Poulsen T, Pedersen JG, and Svenson M: Measurement of human IL-1 by LIF induction, pancreatic islet cell cytotoxicity and bone resorption. Lymphokine Res, in press. 94 Mandrup-Poulsen T, Spinas G, Prowse S, Hansen BS, Jørgensen DW, Bendtzen K, Nielsen JH, and Nerup J: Interleukin-1 effects on isolated islets: influence of islet donor sex, age, strain, and culture conditions. Acta Endocrinol (Suppl) 275: 4A, 1986. 95 Mandrup-Poulsen T, Egeberg J, Nerup J, Bendtzen K, Nielsen JH, and Dinarello CA: Interleukin-1 effects on isolated islets: kinetics and specificity of ultrastructural changes. Acta Endocrinol (Suppl) 275: 29A, 1986. 96 Dinarello CA: Interleukin-1. Rev Infect Dis 6: 51–95, 1984. 97 Malaisse W: Alloxan toxicity to the pancreatic B-cell: a new hypothesis. Biochem Pharmacol 31: 3527–3534, 1982. 98 Spinas GA, Mandrup-Poulsen, Mølvig J, Baek L, Bendtzen K, and Nerup J: Interleukin-1 effects on isolated islets: low concentrations stimulate insulin release. Acta Endocrinol (Suppl) 275: 3A, 1986. 99 Zawalich WS and Diaz VA: Interleukin 1 inhibits insulin secretion from isolated perifused rat islets. Diabetes, in press. 100 Neufeld HA, Pace JG, Kaminsky MV, George DT, Jahrling PB, Wannemacher RW Jr., and Beisel WR: A probable endocrine basis for the depression of ketone bodies during infections or inflammatory states in rats. Endocrinology 187: 596–601, 1980. 101 George DT, Abeles FB, Mapes CA, Sobocinski PZ, Zenser TV, and Powanda MC: Effect of leucocytic endogenous mediators on endocrine pancreas secretory responses. Am J Physiol 233: E240–E245, 1977. 102 Dinarello CA: Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med 311: 1413–1418, 1984. 103 Giulian D and Lachman LB: Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 228: 497–499, 1985. Citing Literature Volume3, Issue3July 1987Pages 779-802 ReferencesRelatedInformation
Referência(s)